CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2014—Nuclea Biotechnologies has partnered with Clinical Reference Laboratory for initial CLIA assay validation and subsequent laboratory processing in support of three of Nuclea’s key tests. Initial efforts will focus on Nuclea’s flagship assay, the Oncogene Science 159 gene-based prostate cancer monitoring test, and its Nuvera breast cancer assay. CRL will also validate the FDA-approved, serum HER2/neu blood test. Nuclea will be responsible for the clinical interpretation of the test results, as well as marketing and distribution of the tests.
Nuclea Biotechnologies, 413-749-4705
Clinical Reference Laboratory, 800-445-6917